ACCOUNT

SECTIONS

HOME
- Homepage
- This Just In
- Chats
- Weather
- Traffic
- Event Guide
- PG Store
- PGe
- Video
- Photos
- The Digs
- RSS Feeds
NEWS
- News Home
- COVID-19
- World
- Nation
- State
- Obituaries
- News Obituaries
- Politics
- Education
- Portfolio
- Science
- Health & Wellness
- Environment
- Aging Edge
- Transportation
- Faith & Religion
- Crimes & Courts
- Social Services
LOCAL
- Local Home
- Region
- City
- North
- East
- West
- South
- Washington
- Westmoreland
- The Neighborhood
- Obituaries
- Classifieds
- Legal Notices
- Real Estate
SPORTS
- Sports Home
- Steelers
- Penguins
- Pirates
- Sports Columns
- Gene Collier
- Ron Cook
- Joe Starkey
- Paul Zeise
- High School Sports
- College Sports
- Pitt
- Penn State
- WVU
- NCAA
- NFL
- MLB
- NBA
- NHL
- North Shore Drive Podcast
OPINION
A&E
- A&E Home
- Celebrities
- Movies
- TV & Radio
- Music
- Concert Listings
- Theatre & Dance
- Art & Architecture
- Books
- Events
LIFE
- Life Home
- Food
- Buying Here
- Homes & Gardens
- Style & Fashion
- Travel
- Restaurants
- Seen
- goodness
- Random Acts of Kindness
- Pets
- Beer Me
- Outdoors
- Holidays
BUSINESS

OTHER

CLASSIFIEDS

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Mineralys Therapeutics, Inc. - Common Stock (NQ:MLYS)

36.29 +0.79 (+2.23%)

Streaming Delayed Price Updated: 4:00 PM EST, Dec 31, 2025 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	1,052,276
Open	35.42
Bid (Size)	36.00 (100)
Ask (Size)	36.65 (300)
Prev. Close	35.50
Today's Range	35.01 - 36.50
52wk Range	8.241 - 47.65
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Fund Discloses Increased Mineralys Bet Amid 200% Stock Run as New Drug Application Nears ↗

December 23, 2025

When a clinical-stage biotech is sitting on nearly $600 million in cash and lining up an FDA filing, sharp investors stop arguing about the past rally and start debating what comes next.

Via The Motley Fool

This Fund Leaned Into 2025's Big Biotech Rally with a $9.5 Million Bet on Mineralys ↗

November 27, 2025

One small fund’s high-conviction move offers a window into how specialists are navigating 2025’s biotech rally.

Via The Motley Fool

Performance

YTD	N/A	N/A
1 Month	-10.9%	-10.9%
3 Month	-8.8%	-8.8%
6 Month	+153.8%	+153.8%
1 Year	+194.8%	+194.8%

More News

MINERALYS THERAPEUTICS INC (NASDAQ:MLYS) Beats Q3 2025 EPS Estimates and Advances Key Drug Candidate ↗

November 10, 2025

Via Chartmill

Earnings Scheduled For November 10, 2025 ↗

November 10, 2025

Via Benzinga

Earnings Preview For Mineralys Therapeutics ↗

August 11, 2025

Via Benzinga

Uncovering Potential: Mineralys Therapeutics's Earnings Preview ↗

November 07, 2025

Via Benzinga

These 2 Healthcare Stocks Are Up Over 100% in a Month. Can They Keep Climbing? ↗

September 21, 2025

Via The Motley Fool

It's a Small World: 3 Stocks Leading the Sudden Rebound in Small Caps ↗

September 16, 2025

Via The Motley Fool

These 2 Healthcare Stocks More Than Doubled Recently and Could Soar Higher, According to Wall Street Analysts ↗

September 07, 2025

Via The Motley Fool

Bruker, Mineralys Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗

September 03, 2025

Via Benzinga

Why Alphabet Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket ↗

September 03, 2025

Via Benzinga

Here are the top movers in Tuesday's session. ↗

September 02, 2025

Via Chartmill

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

September 02, 2025

Via Benzinga

Top movers analysis in the middle of the day on 2025-09-02: top gainers and losers in today's session. ↗

September 02, 2025

Via Chartmill

Air Lease, Ionis Pharmaceuticals, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday ↗

September 02, 2025

Via Benzinga

There are notable gap-ups and gap-downs in today's session. ↗

September 02, 2025

Via Chartmill

Nasdaq Down 1%; Signet Jewelers Earnings Top Views ↗

September 02, 2025

Via Benzinga

Tuesday's pre-market session: top gainers and losers ↗

September 02, 2025

Via Chartmill

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

September 02, 2025

Via Benzinga

Why Carisma Therapeutics Shares Are Trading Higher By 133%; Here Are 20 Stocks Moving Premarket ↗

September 02, 2025

Via Benzinga

AstraZeneca's $80 Billion Ambition Just Got A Big Infusion With New Hypertension Results ↗

August 30, 2025

Via Investor's Business Daily

Nasdaq 100, S&P 500 Hit New All-Time Highs, Airlines Jump: What's Moving Markets Tuesday? ↗

August 12, 2025

Via Benzinga

Earnings Scheduled For August 12, 2025 ↗

August 12, 2025

Via Benzinga

Mineralys Therapeutics: Investigational Drug Shows Benefit In Hypertensive Patients With Chronic Kidney Disease, Stock Jumps ↗

June 17, 2025

Via Benzinga

This Coinbase Global Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗

June 11, 2025

Via Benzinga

Frequently Asked Questions

Is Mineralys Therapeutics, Inc. - Common Stock publicly traded?

Yes, Mineralys Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Mineralys Therapeutics, Inc. - Common Stock trade on?

Mineralys Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Mineralys Therapeutics, Inc. - Common Stock?

The ticker symbol for Mineralys Therapeutics, Inc. - Common Stock is MLYS on the Nasdaq Stock Market

What is the current price of Mineralys Therapeutics, Inc. - Common Stock?

The current price of Mineralys Therapeutics, Inc. - Common Stock is 36.29

When was Mineralys Therapeutics, Inc. - Common Stock last traded?

The last trade of Mineralys Therapeutics, Inc. - Common Stock was at 12/31/25 04:00 PM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.